NUDT18 and neoplasm: We performed in-depth validation of our CRISPR-Cas9 screen in independent isogenic cell clones of three different cell lines that clearly validated that lack of the NUDT18 paralog in chr8pLOH tumor cells sensitized them to NUDT17 ablation.